June 17 in the peptide field looked like a post-conference industry-and-policy day rather than a clinical-trials day. D&D Pharmatech and LG AI Research announced a joint AI-peptide drug-discovery partnership; LG AI's EXAONE Discovery platform will design oral peptide drug candidates while D&D contributes its oral peptide delivery experience, sending D&D shares up roughly 17%. Bloomberg Businessweek published an extended feature on the peptide gold rush, with Janoshik Analytical's Prague-based purity-testing operation reporting that peptide test volume grew 1,200% from 2023 to 2025 alongside the wellness market's mainstreaming. UC San Diego researchers published the first randomized clinical-trial evidence (Nature Communications, May 19, 2026) that semaglutide slowed epigenetic aging by approximately 9% on the DunedinPACE clock and significantly reduced PCGrimAge and PhenoAge scores in 108 adults with HIV-associated lipohypertrophy. And small-cap Azitra (NYSE: AZTR) gained 87% on its June 16 announcement of a filaggrin-based protein and peptide program for cosmetic and cosmeceutical markets ahead of the BIO International Convention on June 23-25. Two backdated items worth surfacing: an Annals of Oncology paper published online June 7 reported that GLP-1 receptor agonists were associated with a 41% lower obesity-associated cancer risk in a 160,000-patient TriNetX target trial emulation; and the Alabama Board of Medical Examiners issued an official notice on May 26 prohibiting state-licensed physicians, PAs, CRNPs, and CNMs from prescribing non-FDA-approved research-grade peptides.